Biotech Values

[genisi]

CANF

One more point is the data we've seen today are from 12 weeks treatment and efficacy tends to get better at 24 weeks. Anyway, I don't see the drug competing with anti-TNFs or even JAK inhibitors, but as monotherapy alternative to methotrexate, in patients who have failed or are refractory to methotrexate or cannot tolerate it (CF101 has a much better safety profile).
There's also an interesting and perhaps appealing point in the fact the drug has a biomarker (A3AR expression levels) that predicts the response.